Guardian Pharmacy Services (NYSE:GRDN) Stock Rating Upgraded by Wall Street Zen

Key Points

• Guardian Pharmacy Services was upgraded to a "buy" rating by analysts at Wall Street Zen, indicating positive sentiment toward the stock.
• Insider transactions showed significant selling, with insider Fred Burke and Director John Ackerman collectively selling over 340,000 shares at an average price of $20.16.
• The company reported a revenue of $329.31 million for the last quarter, exceeding the consensus estimate, despite earnings per share falling slightly short of expectations.

Wall Street Zen upgraded shares of Guardian Pharmacy Services (NYSE:GRDN - Free Report) from a hold rating to a buy rating in a research report report published on Saturday morning.

Several other equities analysts also recently weighed in on the company. Raymond James Financial set a $28.00 price target on Guardian Pharmacy Services and gave the company an "outperform" rating in a report on Wednesday, May 14th. Truist Financial restated a "buy" rating and set a $28.00 price target (up from $25.00) on shares of Guardian Pharmacy Services in a report on Monday, May 19th.

Guardian Pharmacy Services Stock Down 2.1%

Shares of Guardian Pharmacy Services stock traded down $0.43 on Friday, hitting $20.31. The stock had a trading volume of 73,129 shares, compared to its average volume of 153,223. The stock's 50-day simple moving average is $20.93 and its two-hundred day simple moving average is $21.49. Guardian Pharmacy Services has a one year low of $14.16 and a one year high of $26.91.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.21 EPS for the quarter, missing analysts' consensus estimates of $0.22 by ($0.01). The company had revenue of $329.31 million during the quarter, compared to the consensus estimate of $321.21 million. Equities research analysts forecast that Guardian Pharmacy Services will post 0.87 EPS for the current year.

Insider Buying and Selling

In other Guardian Pharmacy Services news, insider Fred Burke sold 138,705 shares of the business's stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $20.16, for a total transaction of $2,796,292.80. Following the completion of the sale, the insider directly owned 413,019 shares in the company, valued at $8,326,463.04. The trade was a 25.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William E. Bindley sold 651,454 shares of the business's stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $20.16, for a total value of $13,133,312.64. Following the sale, the director owned 1,939,817 shares of the company's stock, valued at approximately $39,106,710.72. This represents a 25.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,344,912 shares of company stock worth $228,713,426 in the last three months. 63.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets purchased a new position in Guardian Pharmacy Services in the 4th quarter worth approximately $37,000. KLP Kapitalforvaltning AS purchased a new position in Guardian Pharmacy Services in the 2nd quarter worth approximately $75,000. JPMorgan Chase & Co. purchased a new position in Guardian Pharmacy Services in the 4th quarter worth approximately $77,000. Quantbot Technologies LP purchased a new position in Guardian Pharmacy Services in the 4th quarter worth approximately $81,000. Finally, Corebridge Financial Inc. purchased a new stake in shares of Guardian Pharmacy Services during the 4th quarter worth approximately $87,000.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.